Idexx Laboratories (IDXX) in Pivotal Point Check: AI Software and Pet Boom - Veterinary Specialist Surpasses $1.2 Billion Quarterly Revenue!
Reading Time: 2 minutes
Strong financial figures: Revenue increases by 10% in Q3 to $1.214 billion, significantly surpassing analyst expectations for earnings per share. Drivers of the price gap: In addition to the quarterly results, the raised annual forecast for 2026 and the CoVet acquisition fueled investor interest. Bright future prospects: The high demand in pet diagnostics and recurring revenues ensure profitable growth. IDEXX Laboratories is engaged in veterinary diagnostics and software development for veterinarians. On Monday, November 2, 2026, the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
